Cargando…

Immunological and genetic kinetics from diagnosis to clinical progression in chronic lymphocytic leukemia

BACKGROUND: Mechanisms driving the progression of chronic lymphocytic leukemia (CLL) from its early stages are not fully understood. The acquisition of molecular changes at the time of progression has been observed in a small fraction of patients, suggesting that CLL progression is not mainly driven...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiménez, Isabel, Tazón-Vega, Bárbara, Abrisqueta, Pau, Nieto, Juan C., Bobillo, Sabela, Palacio-García, Carles, Carabia, Júlia, Valdés-Mas, Rafael, Munuera, Magdalena, Puigdefàbregas, Lluís, Parra, Genís, Esteve-Codina, Anna, Franco-Jarava, Clara, Iacoboni, Gloria, Terol, María José, García-Marco, José Antonio, Crespo, Marta, Bosch, Francesc
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8138982/
https://www.ncbi.nlm.nih.gov/pubmed/34016160
http://dx.doi.org/10.1186/s40364-021-00290-z
_version_ 1783695914017226752
author Jiménez, Isabel
Tazón-Vega, Bárbara
Abrisqueta, Pau
Nieto, Juan C.
Bobillo, Sabela
Palacio-García, Carles
Carabia, Júlia
Valdés-Mas, Rafael
Munuera, Magdalena
Puigdefàbregas, Lluís
Parra, Genís
Esteve-Codina, Anna
Franco-Jarava, Clara
Iacoboni, Gloria
Terol, María José
García-Marco, José Antonio
Crespo, Marta
Bosch, Francesc
author_facet Jiménez, Isabel
Tazón-Vega, Bárbara
Abrisqueta, Pau
Nieto, Juan C.
Bobillo, Sabela
Palacio-García, Carles
Carabia, Júlia
Valdés-Mas, Rafael
Munuera, Magdalena
Puigdefàbregas, Lluís
Parra, Genís
Esteve-Codina, Anna
Franco-Jarava, Clara
Iacoboni, Gloria
Terol, María José
García-Marco, José Antonio
Crespo, Marta
Bosch, Francesc
author_sort Jiménez, Isabel
collection PubMed
description BACKGROUND: Mechanisms driving the progression of chronic lymphocytic leukemia (CLL) from its early stages are not fully understood. The acquisition of molecular changes at the time of progression has been observed in a small fraction of patients, suggesting that CLL progression is not mainly driven by dynamic clonal evolution. In order to shed light on mechanisms that lead to CLL progression, we investigated longitudinal changes in both the genetic and immunological scenarios. METHODS: We performed genetic and immunological longitudinal analysis using paired primary samples from untreated CLL patients that underwent clinical progression (sampling at diagnosis and progression) and from patients with stable disease (sampling at diagnosis and at long-term asymptomatic follow-up). RESULTS: Molecular analysis showed limited and non-recurrent molecular changes at progression, indicating that clonal evolution is not the main driver of clinical progression. Our analysis of the immune kinetics found an increasingly dysfunctional CD8(+) T cell compartment in progressing patients that was not observed in those patients that remained asymptomatic. Specifically, terminally exhausted effector CD8(+) T cells (T-bet(dim/−)Eomes(hi)PD1(hi)) accumulated, while the the co-expression of inhibitory receptors (PD1, CD244 and CD160) increased, along with an altered gene expression profile in T cells only in those patients that progressed. In addition, malignant cells from patients at clinical progression showed enhanced capacity to induce exhaustion-related markers in CD8(+) T cells ex vivo mainly through a mechanism dependent on soluble factors including IL-10. CONCLUSIONS: Altogether, we demonstrate that the interaction with the immune microenvironment plays a key role in clinical progression in CLL, thereby providing a rationale for the use of early immunotherapeutic intervention. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40364-021-00290-z.
format Online
Article
Text
id pubmed-8138982
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-81389822021-05-21 Immunological and genetic kinetics from diagnosis to clinical progression in chronic lymphocytic leukemia Jiménez, Isabel Tazón-Vega, Bárbara Abrisqueta, Pau Nieto, Juan C. Bobillo, Sabela Palacio-García, Carles Carabia, Júlia Valdés-Mas, Rafael Munuera, Magdalena Puigdefàbregas, Lluís Parra, Genís Esteve-Codina, Anna Franco-Jarava, Clara Iacoboni, Gloria Terol, María José García-Marco, José Antonio Crespo, Marta Bosch, Francesc Biomark Res Research BACKGROUND: Mechanisms driving the progression of chronic lymphocytic leukemia (CLL) from its early stages are not fully understood. The acquisition of molecular changes at the time of progression has been observed in a small fraction of patients, suggesting that CLL progression is not mainly driven by dynamic clonal evolution. In order to shed light on mechanisms that lead to CLL progression, we investigated longitudinal changes in both the genetic and immunological scenarios. METHODS: We performed genetic and immunological longitudinal analysis using paired primary samples from untreated CLL patients that underwent clinical progression (sampling at diagnosis and progression) and from patients with stable disease (sampling at diagnosis and at long-term asymptomatic follow-up). RESULTS: Molecular analysis showed limited and non-recurrent molecular changes at progression, indicating that clonal evolution is not the main driver of clinical progression. Our analysis of the immune kinetics found an increasingly dysfunctional CD8(+) T cell compartment in progressing patients that was not observed in those patients that remained asymptomatic. Specifically, terminally exhausted effector CD8(+) T cells (T-bet(dim/−)Eomes(hi)PD1(hi)) accumulated, while the the co-expression of inhibitory receptors (PD1, CD244 and CD160) increased, along with an altered gene expression profile in T cells only in those patients that progressed. In addition, malignant cells from patients at clinical progression showed enhanced capacity to induce exhaustion-related markers in CD8(+) T cells ex vivo mainly through a mechanism dependent on soluble factors including IL-10. CONCLUSIONS: Altogether, we demonstrate that the interaction with the immune microenvironment plays a key role in clinical progression in CLL, thereby providing a rationale for the use of early immunotherapeutic intervention. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40364-021-00290-z. BioMed Central 2021-05-20 /pmc/articles/PMC8138982/ /pubmed/34016160 http://dx.doi.org/10.1186/s40364-021-00290-z Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Jiménez, Isabel
Tazón-Vega, Bárbara
Abrisqueta, Pau
Nieto, Juan C.
Bobillo, Sabela
Palacio-García, Carles
Carabia, Júlia
Valdés-Mas, Rafael
Munuera, Magdalena
Puigdefàbregas, Lluís
Parra, Genís
Esteve-Codina, Anna
Franco-Jarava, Clara
Iacoboni, Gloria
Terol, María José
García-Marco, José Antonio
Crespo, Marta
Bosch, Francesc
Immunological and genetic kinetics from diagnosis to clinical progression in chronic lymphocytic leukemia
title Immunological and genetic kinetics from diagnosis to clinical progression in chronic lymphocytic leukemia
title_full Immunological and genetic kinetics from diagnosis to clinical progression in chronic lymphocytic leukemia
title_fullStr Immunological and genetic kinetics from diagnosis to clinical progression in chronic lymphocytic leukemia
title_full_unstemmed Immunological and genetic kinetics from diagnosis to clinical progression in chronic lymphocytic leukemia
title_short Immunological and genetic kinetics from diagnosis to clinical progression in chronic lymphocytic leukemia
title_sort immunological and genetic kinetics from diagnosis to clinical progression in chronic lymphocytic leukemia
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8138982/
https://www.ncbi.nlm.nih.gov/pubmed/34016160
http://dx.doi.org/10.1186/s40364-021-00290-z
work_keys_str_mv AT jimenezisabel immunologicalandgenetickineticsfromdiagnosistoclinicalprogressioninchroniclymphocyticleukemia
AT tazonvegabarbara immunologicalandgenetickineticsfromdiagnosistoclinicalprogressioninchroniclymphocyticleukemia
AT abrisquetapau immunologicalandgenetickineticsfromdiagnosistoclinicalprogressioninchroniclymphocyticleukemia
AT nietojuanc immunologicalandgenetickineticsfromdiagnosistoclinicalprogressioninchroniclymphocyticleukemia
AT bobillosabela immunologicalandgenetickineticsfromdiagnosistoclinicalprogressioninchroniclymphocyticleukemia
AT palaciogarciacarles immunologicalandgenetickineticsfromdiagnosistoclinicalprogressioninchroniclymphocyticleukemia
AT carabiajulia immunologicalandgenetickineticsfromdiagnosistoclinicalprogressioninchroniclymphocyticleukemia
AT valdesmasrafael immunologicalandgenetickineticsfromdiagnosistoclinicalprogressioninchroniclymphocyticleukemia
AT munueramagdalena immunologicalandgenetickineticsfromdiagnosistoclinicalprogressioninchroniclymphocyticleukemia
AT puigdefabregaslluis immunologicalandgenetickineticsfromdiagnosistoclinicalprogressioninchroniclymphocyticleukemia
AT parragenis immunologicalandgenetickineticsfromdiagnosistoclinicalprogressioninchroniclymphocyticleukemia
AT estevecodinaanna immunologicalandgenetickineticsfromdiagnosistoclinicalprogressioninchroniclymphocyticleukemia
AT francojaravaclara immunologicalandgenetickineticsfromdiagnosistoclinicalprogressioninchroniclymphocyticleukemia
AT iacobonigloria immunologicalandgenetickineticsfromdiagnosistoclinicalprogressioninchroniclymphocyticleukemia
AT terolmariajose immunologicalandgenetickineticsfromdiagnosistoclinicalprogressioninchroniclymphocyticleukemia
AT garciamarcojoseantonio immunologicalandgenetickineticsfromdiagnosistoclinicalprogressioninchroniclymphocyticleukemia
AT crespomarta immunologicalandgenetickineticsfromdiagnosistoclinicalprogressioninchroniclymphocyticleukemia
AT boschfrancesc immunologicalandgenetickineticsfromdiagnosistoclinicalprogressioninchroniclymphocyticleukemia